Apimeds Pharmaceuticals US, Inc. (APUS): Total Assets
$164.18M
As of 2025-12-31
$127.62M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $164.18M | n/m | 2026-05-04, Balance as of period end |
| 2024-12-31 | $13.1K | -96.9% | 2026-05-04, Balance as of period end |
| 2023-12-31 | $422.1K | n/a | 2025-04-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $164.18M | n/m |
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $163.18M | +232.2% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $162.40M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $166.13M | +32.5% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $167.74M | -22.8% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $160.46M | -27.2% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $160.43M | +58.2% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $168.19M | +7.9% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $169.01M | -4.7% |
Compare APUS, CYPH, RNAZ, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗